补阳还五汤合升降散加减治疗糖尿病肾病的应用价值分析

文章信息/Info

• Title:补阳还五汤合升降散加减治疗糖尿病肾病的应用价值分析

• 卷期:2023年21卷24期

• 作者:马秀琴  郭宁  王永超△  尹晓华 崔静 于明辰 殷玉兰

• 日照市中医医院风湿肾病科，山东日照276800

• Author(s):MA Xiuqin，GUO Ning，WANG Yongchao△，YIN Xiaohua，CUI Jing，YU Mingchen，YIN Yulan

• Department of Rheumatoid and Nephropathy，Rizhao Hospital of Traditional Chinese Medicine，Rizhao，276800，China

• 关键词补阳还五汤 升降散 糖尿病肾病

• Keywords:Buyang Huanwu decoction; Shengjiang powder; diabetic kidney disease

• 摘要: 目的:观察补阳还五汤合升降散加减对Ⅲ、Ⅳ期糖尿病肾病的治疗效果，为临床实践提供理论依据。方法: 将 80 例糖尿病肾病患者随机分为两组，治疗组采用补阳还五汤合升降散加减，对照组给予洛汀新治疗。治疗 12 周后，观察治疗前后两组临床症状积分、血糖、肾功、24h 尿蛋白定量等的变化。结果: 对Ⅲ、Ⅳ期糖尿病肾病患者，治疗 12 周后，治疗组症状积分、血糖、肾功、尿蛋白定量等均较治疗组改善明显( P＜0. 05) 。结论: 补阳还五汤合升降散治疗糖尿病肾病疗效满意，可以更好的降低尿蛋白，延缓DKD进程，改善生活质量。                                                                                                                                                                                

• Abstract:  To observe clinical effects of modified Buyang Huanwu decoction with Shengjiang powder in the treatment of stage Ⅲ and Ⅳ of diabetic kidney disease (DKD) and to provide a theoretical basis for clinical practice. Methods: All 80 patients were randomized into two groups, 40 cases each group, the control group adopted the therapy of benazepril and the observation group took Buyang Huanwu decoction with Shengjiang powder orally on the foundation of Western medicine, for twelve consecutive weeks. The changes of clinical symptom integral, blood glucose, renal function, and 24h urinary protein quantification in the two groups were observed before and after treatment. Results: For patients with stage Ⅲ and Ⅳ of DKD, after 12 weeks of treatment, the symptom score, blood glucose, renal function and urinary protein quantification in the treatment group were significantly improved compared with the treatment group (p<0. 05). Conclusion: The treatment of modified Buyang Huanwu decoction with Shengjiang powder in DKD can better reduce the urinary protein, delay the DKD process, and improve the quality of life.

  随着经济社会的发展，我国糖尿病人口逐年增多，而糖尿病肾病（diabetic kidney disease，DKD）作为糖尿病最常见的微血管并发症，其发病率也越来越多。据统计，大约⅓的1型糖尿病患者及½的2型糖尿病患者可并发DKD [1]。而DKD则以肾功能损伤伴或不伴蛋白尿为主要表现，目前已经成为我国终末期肾病最主要的病因，其死亡率也居高不下，对经济社会造成了沉重负担。